Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EASY BIO,Inc. (353810.KQ)
KRW6,380.00
+140.00 (+2.24%)
KR KOE Healthcare Biotechnology
Address
6253
Seoul, KR
Seoul, KR
CEO
Il-Hwan Hwang
Website
easybio.co.kr/en/main
IPO
2020-06-05
ISIN KR7353810005
Description
Founded in 2020 and headquartered in Seoul, South Korea, EASY BIO, Inc. offers expert solutions, including specialized feed and dietary supplements, for piglets to customers throughout South Korea and on a global scale.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW6,380.00
+140.00 (+2.24%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
175.7K
Beta
0.39
Float Shares
16.04M
Free Float %
48.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.85% | -9.77% | -17.70% | -13.10% | -6.46% | +9.45% | +22.97% | +58.46% | -7.95% | +528.62% | +528.62% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6,380.00
DCF (Unlevered)
18,012.85
+182.3%
DCF (Levered)
95,233.60
+1,392.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.76
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+24.1% ★ Q1'26: +11.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+45.6% ★ Q1'26: +101.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+5.3% ★ Q1'26: -2.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+9.4% ★ Q1'26: +10.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+18.8% ★ Q1'26: +16.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-2.3% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.85× Q1'26: 2.67× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
88.12B
est: 91.00B (-3.2%)
|
129.46B
est: 91.00B (+42.3%)
|
155.56B
est: 144.90B (+7.4%)
|
165.39B
est: 162.00B (+2.1%)
|
384.33B
est: 384.30B (+0.0%)
|
476.94B
est: 471.90B (+1.1%)
|
510.70B
509.34B – 512.06B
+8.2% YoY
|
554.60B
551.76B – 557.44B
+8.6% YoY
|
| EBITDA |
15.54B
est: 12.39B (+25.4%)
|
17.84B
est: 12.39B (+44.0%)
|
16.77B
est: 19.73B (-15.0%)
|
24.32B
est: 22.05B (+10.3%)
|
42.91B
est: 47.36B (-9.4%)
|
53.32B
est: 58.15B (-8.3%)
|
62.93B
62.76B – 63.10B
+8.2% YoY
|
68.34B
67.99B – 68.69B
+8.6% YoY
|
| EBIT |
14.00B
est: 10.50B (+33.3%)
|
15.15B
est: 10.50B (+44.2%)
|
13.11B
est: 16.72B (-21.6%)
|
20.63B
est: 18.70B (+10.4%)
|
35.40B
est: 39.39B (-10.1%)
|
44.99B
est: 48.37B (-7.0%)
|
52.34B
52.21B – 52.48B
+8.2% YoY
|
56.84B
56.55B – 57.13B
+8.6% YoY
|
| Net Income |
10.43B
est: 18.52B (-43.7%)
|
10.87B
est: 18.52B (-41.3%)
|
9.13B
est: 21.24B (-57.0%)
|
15.54B
est: 24.04B (-35.3%)
|
19.60B
est: 18.39B (+6.6%)
|
27.78B
est: 27.98B (-0.7%)
|
41.40B
41.26B – 41.55B
+48.0% YoY
|
42.76B
41.44B – 44.07B
+3.3% YoY
|
| SGA |
7.72B
est: 11.75B (-34.3%)
|
20.77B
est: 11.75B (+76.7%)
|
27.23B
est: 18.71B (+45.5%)
|
27.18B
est: 20.92B (+29.9%)
|
22.40B
est: 46.96B (-52.3%)
|
25.22B
est: 57.67B (-56.3%)
|
62.41B
62.24B – 62.57B
+8.2% YoY
|
67.77B
67.43B – 68.12B
+8.6% YoY
|
| EPS |
495.30
est: 547.07 (-9.5%)
|
318.50
est: 547.07 (-41.8%)
|
267.47
est: 627.47 (-57.4%)
|
455.00
est: 710.00 (-35.9%)
|
577.04
est: 556.00 (+3.8%)
|
840.00
est: 846.00 (-0.7%)
|
1,252.00
1,247.66 – 1,256.34
+48.0% YoY
|
1,293.00
1,253.26 – 1,332.74
+3.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
67.92B
OE per share TTM
2,052.42
Owner's Yield
32.23%
Maintenance CapEx ratio
5.28%
Maint CapEx / Avg PPE
19.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 6 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 24.6K | 0.46% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 62.5K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 64.9K | 0.28% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 37.5K | 0.39% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 699.94 | 0.56% |
| 6 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 1.9K | 0.33% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Executive team data is not available for this company yet.
EBIT / Employee
310.27M
Shares Outstanding
33.08M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
ESG Score History
No data available for this company.
Company data will be available after the next weekly refresh.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 353810.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
